Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir/lamivudine plus darunavir/ritonavir versus abacavir/lamivudine plus raltegravir in antiretroviral-naive late presenters with advanced HIV disease
2011-005973-21Phase 3Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Abacavir + lamivudine + darunavir + ritonavir with Abacavir + lamivudine + raltegravir (2 arms). Primary endpoint: Virologic suppression at week 48. Started Mar 2012; status: completed.
02
Drugs
abacavirlamivudinedarunavirritonavirraltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-005973-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005973-21.